Legemiddelutvikling

Eksperter: (Klikk på et navn for nærmere beskrivelse)


Telefon: +4777646657
Forskningsinteresser:

 

Conference presentations

9) Dominik Ausbacher; Lindsey A. Lorenz; Darla M. Goeres; Philip S. Stewart ; Morten B. Strøm; Pia M. Vuorela; Adyary Fallarero. Antimicrobial β2,2-amino acid derivatives eliminate Staphylococcus aureus biofilms by membrane disruption and biomass removal. DPhG Annual Meeting, Munich (2016).

8) Leena Hanski, Dominik Ausbacher; Morten B. Strøm; Pia M. Vuorela. Impact of β2,2-amino acid derivatives, a novel class of Chlamydia pneumoniae inhibitors, on bronchial epithelium VEGF production. Conference on Lung and Respiratory Care, Manchester (2016).

7) Adyary Fallarero, Malena Skogman, Vânia Moreira, Suvi Manner, Dominik Ausbacher, Reko Leino, Morten B. Strøm, Jari Yli-Kauhaluoma, Pia M. Vuorela. The challenges of discovering new anti-biofilm probes from a high-throughput screening (HTS) perspective. Eurobiofilms 2013 - 3rd European Congress on Microbial Biofilms - Basic and Clinical Aspects, Ghent (2013).

6) Leena Pohjala, Dominik Ausbacher, Morten B. Strøm, Pia M. Vuorela. Inhibition of Chlamydia pneumoniae infectivity by β-amino acid derivatives mimicking cationic antimicrobial peptides. 7th meeting of the European society for Chlamydia research, Amsterdam (2012).

5) Dominik Ausbacher, Janni Kujala, Pia M. Vuorela, Morten B. Strøm, Adyary Fallarero. Control of Staphylococcus aureus biofilm with highly active β2,2-amino acid derivatives. 3rd International Symposium on Antimicrobial Peptides, Lille (2012).

4) Dominik Ausbacher, Terkel Hansen, Gunbjørg Svineng, Morten B. Strøm. Mechanisms of cancer cell death induced by novel cationic β-peptidomimetics. 22nd American Peptide Symposium, San Diego (2011).

3) Terkel Hansen, Dominik Ausbacher, Martina Havelkova, Morten B. Strøm. Bactericidal activity of small β-peptidomimetics. 31. European Peptide Symposium, Copenhagen (2010).

2) Veronika Tørfoss, Dominik Ausbacher, Terkel Hansen, Martina Havelkova, Morten B. Strøm Anticancer activity of small cationic β-peptidomimetics. 31. European Peptide Symposium, Copenhagen (2010).

1) C. Becker, A. Ehmer, A. Maschke, A. Meindorfer, D. Ausbacher, J. Tessmar, T. Blunk, A. Goepferich. Influence of Micronisation of Proteins on the Properties of Lipid Microparticles for Controlled Release. DPhG Joint Meeting, Marburg (2006).

 

Publications

15) Paulsen, M.H.; Karlsen, E.A.; Ausbacher, D.; Anderssen, T.; Bayer, A.; Ochtrop, P.; Hedberg, C.; Haug, T.; Ericson Sollid, J.U.; Strøm M.B. (2018). An amphipathic 13-membered cyclic tetrapeptide scaffold containing β2,2-amino acids with activity against multi-resistant bacteria. Journal of Peptide Science (accepted).

14) Ausbacher, D; Lorenz, L.A.; Pitts, B.; Stewart, P.S.; Goeres, D.M. (2017). Paired methods to measure biofilm killing and removal: a case study with Penicillin G treatment of Staphylococcus aureus biofilm. Letters in Applied Microbiology. DOI: 10.1111/lam.12843.

13) Eksteen, J.J.; Ausbacher, D.; Simon-Santamaria, J.; Stiberg, T.; Cavalcanti-Jacobsen, C.; Wushur, I.; Svendsen, J.S.; Rekdal, Ø. (2016). Iterative Design and in Vivo Evaluation of an Oncolytic Antilymphoma Peptide. Journal of Medicinal Chemistry. DOI: 10.1021/acs.jmedchem.6b00839.

12) Paulsen, M.H.; Engqvist, M.; Ausbacher, D.; Strøm, M. B.; Bayer, A. (2016). Efficient and scalable synthesis of α,α-­disubstituted β-amino amides. Organic and biomolecular chemistry . ISSN 1477-0520.s DOI: 10.1039/C6OB01219A.

11) Hanski, L.#; Ausbacher, D.#; Tiirola, T.M.; Strøm, M.B.; Vuorela, P.M. (2016). Amphipathic β2,2-amino acid derivatives suppress infectivity and Ddsrupt the intracellular replication cycle of Chlamydia pneumoniae. PLoS ONE, 11(6). DOI: 10.1371/journal.pone.0157306. #contributed equally

10) Sivertsen, A.; Tørfoss, V.; Isaksson, J.; Ausbacher, D.; Anderssen, T.; Brandsdal, B. O.; Havelkova, M.; Skjørholm, A. E.; Strøm M.B. (2013). Anticancer potency of small linear and cyclic tetrapeptides and pharmacokinetic investigations of peptide-binding to human serum albumin. J. Pept. Sci., 20: 279-291.

9) Ausbacher, D.; Fallarero, A.; Kujala, J.; Määttänen, A; Jouko, Peltonen; Strøm, M.B.; Vuorela, P.M. (2014). Staphylococcus aureus biofilm susceptibility to small and potent β2,2-amino acid derivatives. Biofouling, 30: 81-93.

8) Ausbacher, D.; Svineng, G.; Hansen, T.; Strøm M.B. (2012). Anticancer mechanisms of action of two small amphipathic β2,2-amino acid derivatives derived from antimicrobial peptides. Biochimica et Biophysica Acta (BBA) - Biomembranes, 1818: 2917-2925.

7) Hansen, T.; Ausbacher, D.; Zachariassen, Z.G.; Anderssen, T.; Havelkova, M.; Strøm M.B. (2012) Anticancer activity of small amphipathic β2,2-amino acid derivatives, European Journal of Medicinal Chemistry, 58: 22-29.

6) Tørfoss, V.; Isaksson, J.; Ausbacher, D.; Brandsdal, B. O.; Flaten, G. E.; Anderssen, T.; Cavalcanti-Jacobsen, C. de A.; Havelkova, M.; Nguyen, L. T.; Vogel, H. J.; Strøm, M. B. (2012) Improved anticancer potency by head-to-tail cyclisation of short cationic anticancer peptides containing a lipophilic β2,2-amino acid, Journal of Peptide Science, 18: 609-619.

5) Tørfoss, V.; Ausbacher, D.; Cavalcanti-Jacobsen, C.deA.; Hansen, T.; Brandsdal, B-.O.; Havelkova, M.; Strøm, M.B. (2011): Synthesis of anticancer heptapeptides containing a unique lipophilic β2,2-amino acid building block, Journal of Peptide Science 18: 170-176.

4) Hansen, T.; Ausbacher, D.; Flaten, G. E.; Havelkova, M.; Strøm, M. B.(2011): Synthesis of cationic antimicrobial β2,2-amino acid derivatives with potential for oral administration, Journal of Medicinal Chemistry 54: 858-868.

3) Hupfeld, S.; Moen, H. H.; Ausbacher, D.; Haas, H.; Brandl, M. (2010): Liposome fractionation and size analysis by asymmetrical flow field-flow fractionation/multi-angle light scattering: influence of ionic strength and osmotic pressure of the carrier liquid. Chemistry and Physics of Lipids 163: 141-147.

2) Hupfeld, S.; Ausbacher, D.; Brandl, M. (2009): Asymmetric flow field-flow fractionation of liposomes: 2. Concentration-detection and adsorptive loss phenomena. Journal of Separation Science 32: 3555-3561.

1) Hupfeld, S.; Ausbacher, D.; Brandl, M. (2009): Asymmetric flow field-flow fractionation of liposomes: optimization of fractionation variables. Journal of Separation Science 32: 1465-1470.


Stipends

Personal overseas research grant of the Research Council of Norway (2014/15)

UiT transition grant for recruitment of young researchers (2012/13)

UiT mobility grant for research abroad (2011)

Travel grant of the Norwegian Pharmaceutical Society (2011)

 

Studies and Education

03/2015 - 08/2015                                                                                                                                         Postdoc, Center for Biofilm Engineering, Standardized Biofilm Methods Laboratory, Assistant Prof. D. Goeres and Biofilm Control Laboratory, Prof. P.Stewart, Montana State University, Bozeman, USA

09/2014 - 02/2015                                                                                                                                            Postdoc, Faculty of Pharmacy, Division of Pharmaceutical Biosciences, Anti-infective Research Laboratory, Adjunct Prof. A. Fallarero and Prof. P. Vuorela, University of Helsinki, Finland

03/2013 - present
Postdoc, Faculty of Health Sciences, Natural Products and Medicinal Chemistry Research Group, Prof. M. B. Strøm, UiT-The Arctic University of Norway

11/2012 - 02/2013
Researcher, Faculty of Health Sciences, UiT-The Arctic University of Tromsø

11/2012
PhD thesis defence: Biological activity of β2,2-amino acid derivatives derived from antimicrobial peptides- Investigations of Antimicrobial and Anticancer Activity and the Mechanisms of Action

11/2011 - 02/2012                                                                                                                                          Visiting PhD student, Pharmacutical Sciences Laboratory, Prof. P. Vuorela, Åbo Akademi University, Turku, Finland

10/2008 - 09/2012
Ph.D. student, Faculty of Health Sciences, Natural Products and Medicinal Chemistry Research Group Prof. M. B. Strøm, UiT-The Arctic University of Norway

07/2008 and 12/2012
Licensure for the profession as pharmacist in Germany and Norway

10/2007
Diploma defence, A4F/MALS Analysis of Liposomes, Faculty of Biosciences, Department of Pharmaceutical Technology Prof. K. Mäder, University of Halle, Germany

05/2007 - 10/2007
Diploma student, Faculty of Health Sciences, Drug Transport and Delivery Research Group Prof. M. Brandl, UiT-The Arctic University of Norway

04/2007
Second State Exam

08/2004
First State Exam

10/2002 - 04/2007
Pharmacy studies, University of Regensburg, Germany

06/2001
Karlsgymnasium Bad Reichenhall, University-entrance diploma

 

Languages

German (native)
English
Norwegian

 

Work experience

09/2008
Researcher for Epitarget AS, Oslo

11/2007 - 04/2008
Pharmacist in practical training, Ahorn Apotheke, Regensburg

09/2006 - 10/2006
Aenova Sales Pharma - Dragenopharm-Apotheker Püschel GmbH & Co. KG, Tittmoning

07/2001 - 06/2002                                                                                                                                           Service in the mountain infantry batallion Berchtesgaden, Armed forces of Germany


Telefon: +4777646169
Forskningsinteresser:

Permeabilitet over biologiske barrierer. (Snurr film under for mer informasjon)

 

The phospholipid vesicle-based permeation assay (PVPA)

Liposomer som legemiddelbærer

Liposomer som modellsystem for celler og bakterier i interaksjonsstudier

Delivery av lipofile virkestoff

 


Publikasjonsliste

Cand.Pharm. avhandling
Incorporation of Camptothecin in liposomes, metod development and incorporation efficacy screening using different liposome formulations (June 2003)

PhD avhandling
The Phospholipid Vesicle-Based Barrier: A Novel Method for Passive Drug Permeability Screening (June 2007)

 

Populærvitenskapelige publikasjoner online

Forskningspodcast fra UiT Norges arktiske universitet (2018)

Hvordan velge de beste kandidatene for fremtidens legemidler? (2018)

42 millioner kroner for utvikling av persontilpasset medisin (2018)

Så lenge holder solkremen din (2017)

Er det sant at man må kaste solkremen etter ett år? (2016)

Skammelig nedprioritering (2016)

Er kvinnesykdommer mindre viktige? (2016)

Skammelig nedprioritering av forskning på kvinnesykdommer (2016)

Finner de beste legemidlene- uten dyreforsøk (2015)

How long before it hits (2014)

Gjennombrudd: Dyreforsøk med brannskader kan erstattes (2014)

Hermer stoffopptak via hud og tarm (2012)

Legemidler og barrierer (2012)

 

Publikasjoner i internasjonale peer-reviewed journaler

36) M. Falavigna, M. Klitgaard, E. Steene and G. E. Flaten (2019) Mimicking regional and fasted/fed state conditions in the intestine with the mucus-PVPA in vitro model: the impact of pH and simulated intestinal fluids on drug permeability, European Journal of Pharmaceutical Sciences, accepted
35) S. Ternullo, P. Basnet, A. M. Holsæter, G. E. Flaten, L. de Weerd, N. Škalko-Basnet (2018) 
Deformable liposomes for skin therapy with human epidermal growth factor: The effect of liposomal surface charge. European Journal of Pharmaceutical Sciences, in press, doi:10.1016/j.ejps.2018.10.005
34) P. Berben, A. Bauer-Brandl, M. Brandl, B. Faller, G. E. Flaten, A. Jacobsen, J. Brouwers and P. Augustijns (2018)
Drug Permeability Profiling using Cell-Free Permeation Tools: An Overview and Their Applications, EurJPharmSci, 119, p 219-233 (open access)
33) M. Falavigna, M. Klitgaard, C.  Brase, S.  Ternullo, N. Škalko-Basnet, G. E. Flaten (2018)
Mucus-PVPA (Mucus Phospholipid Vesicle-based Permeation Assay): an artificial permeability tool for drug screening and formulation development, Int J Pharm, DOI: 10.1016/j.ijpharm.2017.12.038
32) S. Ternullo, L. de Weerd, A. M. Holsæter, G. E. Flaten, N. Škalko-Basnet (2017)
Going skin deep: a direct comparison of penetration potential of lipid-based nanovesicles on the isolated perfused human skin flap model, European Journal of Pharmaceutics and Biopharmaceutics, 121, 14-23
30) J. Kumari, G. E. Flaten, N. Škalko-Basnet and H. Tveiten (2017) 
Molecular transfer to Atlantic salmon ovulated eggs using liposomes, Aquaculture, 479, 404–411
29) T. Andersen, E. Mishchenko, G. E. Flaten, J. Sollid, S. Mattsson, I. Tho and N. Skalko-Basnet (2017)
Chitosan-based nanomedicine to fight genital Candida infections: Chitosomes, Marine Drugs, 15, 64, doi:10.3390/md15030064
28) S. Ternullo, L. de Weerd, G. E. Flaten, A. M. Holsæter and N. Skalko-Basnet (2017)
The isolated perfused human skin flap model: A missing link in skin penetration studies? European Journal of Pharmaceutical Sciences,  96(1), 334-341
27) A. Engesland, N. Škalko-Basnet, G. E. Flaten (2016)
In vitro models to estimate drug penetration through the compromised stratum corneum barrier, Drug Development and Industrial Pharmacy, 421751, http://www.tandfonline.com/doi/full/10.3109/03639045.2016.1171334
26) E. Naderkhani, T. Vasskog, G.E. Flaten (2015)Biomimetic PVPA in vitro model for estimation of the intestinal drug permeability using fasted and fed state simulated intestinal fluids, European Journal of Pharmaceutical Sciences, 73, 64-7
25) G.E Flaten, Z. Palac, A.Engesland, J. Filipović-Grčić, Ž. Vanić and N. Škalko-Basnet (2015) In vitro skin models as a tool in optimization of drug formulation, European Journal ofPharmaceutical Sciences, 75, 10–24
24) T. Andersen, S. Bleher, G.E. Flaten, I. Tho, S. Mattsson, N. Skalko-Basnet (2015) Chitosan in mucoadhesive drug delivery: Local vaginal therapy, Marine Drugs,13, 222-236
23) A. Engesland, N. Škalko-Basnet, G.E. Flaten (2015) PVPA and EpiSkin® in Assessment of Drug Therapies Destined for Skin Administration, Journal of Pharmaceutical Sciences, 104, 1119-1127
22) S.Fulsundar, K. Harms, G.E. Flaten, P. Johnsen, B. Chopade, and K. Nielsen (2014) Gene transfer potential of outer membrane vesicles of Acinetobacter baylyi and effects of stress on vesiculation, Applied and Environmental Microbiology, 80(11), 3469–3483 
21) E. Naderkhani , J. Isaksson, A. Ryzakov, G.E. Flaten (2014) Development of a biomimetic phospholipid vesicle-based permeation assay (PVPA) for the estimation of intestinal drug permeability, Journal of Pharmaceutical Sciences, 103:1882–1890
20) Z. Palac, A. Engesland, G.E. Flaten, N. Škalko-Basnet, J. Filipović-Grčić, Ž. Vanić (2014) Liposomes for (trans)dermal drug delivery: the skin-PVPA as a novel in vitro stratum corneum model in formulation development, Journal of Liposome Research,  24(4): 313–322
19)  E. Naderkhani,  A. Erber, N. Škalko-Basnet, G.E. Flaten (2014) Improved permeability of acyclovir: Optimization of mucoadhesive liposomes using the PVPA model,  Journal of Pharmaceutical Sciences, 103, 661-668
18) T. Andersen, Ž. Vanić, GE Flaten, S. Mattsson, I. Tho, N. Škalko-Basnet (2013) Pectosomes and chitosomes as delivery systems for metronidazole: The one-pot preparation method, Pharmaceutics, special issue on Liposome Technology, 5: 445-456 
17) Whitaker, RD.; Ingebrigsten, SG; Naderkhani, E; Skar, M L; Flaten, GE (2013) Investigation of parameters influencing incorporation, retention and cellular cytotoxicity in liposomal formulations of poorly soluble camptothecin, Journal of Liposome Research, 23(4), 298-310
16) Engesland, A.; Skar, M.; Hansen, T.; Skalko-Basnet, N.; Flaten, G. E. (2013) New Applications of PVPA: Permeation Model Mimicking Skin Barrier, Journal of Pharmaceutical Sciences, 102:1588-1600
15) Flaten, G. E.; Chang, T. T.; Phillips, W; Brandl, M.; Bao, A. and Goins, B Liposomal Formulations of Poorly Soluble Camptothecin -Drug Retention and Biodistribution, Journal of Liposome Research (2013),  23(1), 70-81
14) V. Tørfoss, J. Isaksson, D, Ausbacher, B.O. Brandsdal, G. E. Flaten, T. Anderssen,  C. de A. Cavalcanti-Jacobsen, M. Havelkova, L. T. Nguyen,  H. J. Vogel,M. B. Strøm Improved anticancer potency by head-to-tail cyclisation of short cationic anticancer peptides containing a lipophilic ß2,2-amino acid, Journal of Peptide Science (2012), 18(10), 609-619
13) J. Isaksson, B.O. Brandsdal, M. Engqvist, G. E. Flaten, J .S. Svendsen and W. Stensen A Synthetic Antimicrobial Peptidomimetic (LTX 109): Stereochemical Impact on Membrane Disruption, J Med Chem (2011) 54, 5786-5795
12) S.M. Fischer, G. E. Flaten, E. Hagesæther, G. Fricker, M. Brandl In Vitro Permeability of Poorly Water Soluble Drugs in the Phospholipid Vesicle-Based Permeation Assay (PVPA): The Influence of Non-Ionic Surfactants,  J Pharm Pharmacol 2011, 63, 1022-1030
11) G.E. Flaten, K. Gabor, W. Stensen, G. Isaksen, R. Karstad, J.S. Svendsen, H. Daniel, and J.Svenson In vitro characterisation of human peptide transporter hPEPT1 interactions and passive permeation studies of short cationic antimicrobial peptides, J Med Chem 2011 54(7), 2422-2432
10) T.Hansen, D.Ausbacher, G. E. Flaten, M. Havelkova, and M. B. Strøm Synthesis of cationic antimicrobial β2,2-amino acid derivatives with potential for oral administration, J Med Chem 2011 , 54 (3), 858–868
9) J.Kanzer, I. Tho, G.E. Flaten, M. Maegerlein, P. Hoelig, G. Fricker, M. Brandl In-vitro permeability screening of melt extrudate formulations containing poorly water-soluble drug compounds using the phospholipid veicle-based barrier, Journal of Pharmacy and Pharmacology,2010, 62: 1591–1598
8) J. Svenson,  R. Karstad, G. E. Flaten, B. Brandsdal, M. Brandl, J. S. Svendsen Altered activity and physico-chemical properties of short cationic antimicrobial peptides by incorporation of arginine analogs, Mol. Pharm, vol 6, no 3, 996-1005 (2009)
7) G. E. Flaten, O. Awoyemi, K. Luthman, M. Brandl, U. Massing The phospholipid vesicle-based permeability assay: 5. Development towards an automated procedure for high throughput permeability screening, JALA, 14, 12-21 (2009)
6) M. Brandl, G.E. Flaten and A. Bauer-Brandl Passive Diffusion Across Membranes in Hoboke (ed) Wiley Encyclopedia of Chemical Biology, John Wiley and Sons, 3, 541-550 (2009) 
5) G. E. Flaten, K. Luthman, T. Vasskog, M. Brandl  Drug permeability across a phospholipid vesicle-based barrier: 4. The effect of tensides, co-solvent and pH changes on barrier integrity and on drug permeability, Eur. J. Pharm. Sci. 34, 173-180 (2008)
4) G.E Flaten, M.L. Skar, K. Luthman, M. Brandl Drug permeability across a phospholipid vesicle-based barrier: 3. Characterization of drug-membrane interactions and the effect of agitation on barrier integrity and on the permeability, Eur. J. Pharm. Sci. 30, 324-332 (2007)
3) G. E. Flaten, H. Bunjes, K. Luthman, M. Brandl Drug permeability across a phospholipids vesicle-based barrier: 2. Characterization of barrier structure, storage stability and stability towards pH changes, Eur. J. Pharm. Sci. 28, 336-343 (2006).
2) G. E. Flaten, A.B. Dhanikula, K. Luthman, M.Brandl Drug permeability across a phospholipid vesicle barrier: a novel approach for studying passive diffusion, Eur. J. Pharm. Sci. 27, 80-90 (2006).
1) A.M. Sætern, G.E. Flaten, M. Brandl A method to determine the incorporation capacity of Camptothecin in liposomes AAPS PharmSciTech 5 (3) article 40 (2004)
 

 


Telefon: +4777646719
Forskningsinteresser:

Mine forskningsinteresser samsvarer med forskningsinteressene til gruppa "Drug transport and delivery".

og angår formulering og optimalisering av legemiddelformuleringer for topical- (sårbehandling) og systemisk- (injeksjonsmedisin) administrasjo mtp:

  • Holdbarhet/stabilitet
  • Brukervennlighet
  • Effekt
  • Bivirkningsprofil
  • Fremstillingsmetode

 

Karakterisering av legemiddelformuleringens fysikalskjemiske-, biofarmasøytiske- og kliniske/terapeutiske egenskaper skjer vha a in vitro, ex vivo og in vivo testing.

 

 


Telefon: +4777644070
Forskningsinteresser:
  • Makromolekylers struktur og funksjon
  • Det molekylære opphav til enzymers kuldeadaptasjon
  • Utvikling av enzymer for anvendelse
  • Bioprospektering

Telefon: +4777644085
Forskningsinteresser:

 

1) Design, synthesis and development of antimicrobial and anticancer peptides and peptidomimetics as lead-compounds for drug-development and investigation of pharmacophore models.

2) Design and synthesis of peptidomimetics and bioactive scaffolds for optimization of potency and pharmacokinetic properties.

3) Isolation and structural elucidation of marine bioactive compounds from Arctic and sub-Arctic marine invertebrates and synthesis of marine natural product mimics (marine bio-prospecting).

 

Veiledning av PhD studenter

2000 – 2004: Biveileder for Dr. Morten K. Moe - Tittel på PhD avhandling: ESI low-energy tandem MS characterisation of lipids modified by a novel derivatisation method. Finansiert av Norges Forskningsråd.

2007 – 2010: Biveileder for Dr. Margey Tadesse - Tittel på PhD avhandling: Antimicrobial natural products from Arctic and sub-Arctic marine invertebrates. Finansiert av UiT.

2007 – 2011: Hovedveileder for Dr. Terkel Hansen (cand. pharm.) - Tittel på PhD avhandling: Antimicrobial and anticancer beta-peptidomimetics – synthesis and biological evaluation of a new class of small and highly potent compounds. Finansiert av UiT.

2008 – 2012: Hovedveileder for Dominik A. Ausbacher (cand. pharm.) - Tittel på PhD avhandling: Biological activity of β2,2-amino acid derivatives derived from antimicrobial peptides - Investigations of antimicrobial and anticancer activity and the mechanisms of action. Finansiert av UiT.

2008 – 2013: Hovedveileder for Veronika Tørfoss (cand. pharm.) - Tittel på avhandling: Short anticancer peptides containing a lipophilic β2,2-amino acid - Synthesis and biological evaluation of linear and cyclic hepta-, hexa-, penta-, and tetrapeptides. Finansiert av Norges Forskningsråd (KOSK-II programmet).

2011 – 2015: Biveileder for Elisabeth Klungerbo Olsen (cand. pharm.) - Tittel på avhandling: Bioprospecting of Arctic marine organisms. Finansiert av MabCent – SFI.

2011 – pågående prosjekt: Hovedveileder for Elizaveta Mikhailovna Igumnova - Arbeidstittel: Chemical synthesis, isolation, and structural characterization of marine bioactive hit compounds. Finansiert av MabCent – SFI.

2011 – 2016: Biveileder for Runar Gjerp Solstad - Tittel på avhandling: Discovery of antimicrobial peptides in two invertebrates, the sea anemone Urticina eques and the sea urchin chinus esculentus - Isolation, characterization and structure-activity relationship studies. Finansiert av UiT.

2012 - 2017: Hovedveileder for Marianne Hagensen Paulsen - Tittel på avhandling: Synthetic mimics of antimicrobial peptides. Synthesis and biological studies of novel synthetic mimics of antimicrobial peptides. Finansiert av Norges Forskningsråd og UiT - "Fellesløftet".

2014 - 2017: Biveileder for Thomas Aleksander Bakka (NTNU - Trondheim) - Tittel på avhandling: Synthesis and antimicrobial evaluation of small molecule amphiphiles derived from amphiphilic antimicrobial natural products. Finansiert av NTNU.

2018 - pågående prosjekt: Biveileder for Manuel Karl Langer (Institutt for kjemi - IKJ, UiT) - Arbeidstittel: Synthesis of new antimicrobial, antibiofilm and antifouling agents. Finansiert av UiT - Norges arktiske universitet - "Tematiske satsninger".

2018 - pågående prosjekt : Hovedveileder for Danijela Simonovic (Institutt for farmasi - IFA, UiT) - Arbeidstittel: Synthesis of antimicrobial amphipathic scaffolds targeting multi-resistant bacteria. Finansiert av UiT - Norges arktiske universitet - "Tematiske satsninger" - LEADScAMR.

2018 - pågående prosjekt: Biveileder for Christoffer Ågnes Sivertsen (Fakultet for biovitenskap, fiskeri og økonomi - BFE, NFH UiT) - Arbeidstittel: Antibacterial and antibiofilm compounds in Arctic and sub-Arctic invertebrates. Finansiert av UiT - Norges arktiske universitet - "Tematiske satsninger" - AntifoMar.

2019 - pågående prosjekt: Biveileder for Susannah von Hofsten (Institutt for medisinsk biologi - IMB, UiT) - Arbeidstittel: Identifisering og utvikling av anticancer peptider og peptidomimetika for målrettet behandling av kreft. Finansiert av UiT - Norges arktiske universitet.

 

Veiledning av masterstudenter

Jeg har siden 2003 vært veileder for 28 mastergradsstudenter i farmasi / legemiddelkjemi / organisk kjemi.

 


Telefon: +4777620909